Zacks Investment Research
13 Aug 2026, 13:55 UTC · 1h ago
Edwards Climbs 14% in 3 Months as Growth Strength Tests Valuation
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Zacks Investment Research
13 Aug 2026, 13:55 UTC · 1h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
4 claims · each scored for market impact
Edwards Lifesciences (EW) raised its 2026 TMTT sales outlook to a range of $760-$780 million. — Upward revisions to revenue guidance typically signal strong demand and positive future earnings potential.
+0.40Edwards Lifesciences' TMTT sales grew 44.8% at constant currency to $195.9 million in the second quarter. — Significant growth in a high-growth franchise proves the scalability of the newer therapy platforms.
+0.30Edwards Lifesciences trades at 28.8X forward 12-month EPS, which is higher than the S&P 500 (20.7X) and its sub-industry (27.3X). — A premium valuation relative to benchmarks limits further upside and increases sensitivity to any execution misses.
-0.20Continue reading
6 related stories
Search tags
Second-quarter TAVR sales reached $1.26 billion, representing a 10.5% increase at constant currency. — Steady growth in the company's largest revenue platform provides a stable financial foundation.
Which stocks this story touches
Strong growth in structural-heart franchises and double-digit expansion in TAVR and TMTT sales.
Mentioned as a relevant competitor with a supported TAVR platform, but no specific positive or negative catalyst provided.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Zacks Investment Research
1h ago
